VIR
Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting SARS-CoV-2, hepatitis B virus, influenza A, human immunodeficiency virus and tuberculosis.
Vir Biotechnology, Inc. (VIR) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B+); its weakest is Growth (F). The rating has held at C for 5 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-15 | B- (3.0) | F (0.1) | C- (2.1) | B+ (3.6) | C+ (2.6) | C (2.3) |
| 2026-11-08 | B- (3.0) | F (0.4) | C- (2.1) | A- (4.1) | C+ (2.6) | C (2.4) |
| 2026-11-01 | B- (3.0) | F (0.5) | C- (2.1) | B+ (3.8) | C+ (2.7) | C (2.4) |
| 2026-10-25 | B- (3.0) | F (0.5) | C- (2.0) | B (3.4) | C+ (2.6) | C (2.3) |
| 2026-10-18 | B- (3.0) | F (0.4) | C- (2.0) | B- (3.1) | C+ (2.6) | C (2.2) |